SCHEMBL2575993

SCHEMBL2575993

NC(=O)OC(O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.50
CYP1A2 P05177 1/20 0.50
PKM P14618 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
LMNA P02545 4/20 0.46
MAPK1 P28482 2/20 0.46
BCAT2 O15382 1/20 0.44
SRC P12931 1/20 0.43
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
ALOX5 P09917 1/20 0.41
EPHX1 P07099 1/20 0.41
CTSD P07339 1/20 0.41
KMT2A Q03164 1/20 0.41
ADORA3 P0DMS8 1/20 0.40
EDNRB P24530 1/20 0.40
MC4R P32245 1/20 0.40
CYP2C19 P33261 1/20 0.40
DRD3 P35462 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5932263 0.80 LMNA (0.48) CYP2D6CYP1A2PKMSMN1; SMN2NPSR1
SCHEMBL5306707 0.80 CYP2D6 (0.52) CYP2D6CYP1A2PKMSMN1; SMN2NPSR1
SCHEMBL1955 0.80 ESR1 (0.53) CYP2D6CYP1A2PKMSMN1; SMN2NPSR1
SCHEMBL29816355 0.80 CYP2D6 (0.52) CYP2D6CYP1A2PKMSMN1; SMN2NPSR1
SCHEMBL5933696 0.78 LMNA (0.46) CYP2D6CYP1A2PKMSMN1; SMN2NPSR1
SCHEMBL446690 0.78 CYP2D6 (0.50) CYP2D6CYP1A2PKMSMN1; SMN2NPSR1
SCHEMBL9389474 0.78 ESR1 (0.52) CYP2D6CYP1A2PKMSMN1; SMN2NPSR1
SCHEMBL11096012 0.78 LMNA (0.39) CYP2D6CYP1A2PKMSMN1; SMN2NPSR1
SCHEMBL5062426 0.78 ALDH1A1 (0.56) CYP2D6LMNAMAPK1SRCCES2
SCHEMBL6497920 0.78 CYP1A2 (0.46) CYP2D6CYP1A2PKMSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108617-A1 AUTO-TUNING DRUG REGULATOR CONSTRUCTIONS RETHINK64 BIONETWORKS PBC (US) 2026-04-23 US disclosed
WO-2024155707-A1 AUTO-TUNING DRUG REGULATOR CONSTRUCTIONS RETHINK64 BIONETWORKS PBC (US) 2024-07-25 WO disclosed
WO-2024010810-A2 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2024-01-11 WO disclosed
EP-2751076-A1 SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES Spirogen Sàrl (CH) 2014-07-09 EP disclosed
WO-2013053872-A1 SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES SPIROGEN SÀRL (CH) 2013-04-18 WO disclosed
EP-2558445-A1 INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES Spirogen Sàrl (CH) 2013-02-20 EP disclosed
WO-2011128650-A1 INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES SPIROGEN LIMITED (GB) 2011-10-20 WO disclosed
US-5561119-A ANTITUMOR AGENTS LABORATOIRES HOECHST (FR) 1996-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108617-A1 AUTO-TUNING DRUG REGULATOR CONSTRUCTIONS TPMT, CYP2D6, ACHE CYP2D6 2/4885CYP1A2 118/4885PKM 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.